ZA200404584B - Pharmaceutical compositions of orally active taxane derivatives having enhanced bioavailability. - Google Patents
Pharmaceutical compositions of orally active taxane derivatives having enhanced bioavailability. Download PDFInfo
- Publication number
- ZA200404584B ZA200404584B ZA200404584A ZA200404584A ZA200404584B ZA 200404584 B ZA200404584 B ZA 200404584B ZA 200404584 A ZA200404584 A ZA 200404584A ZA 200404584 A ZA200404584 A ZA 200404584A ZA 200404584 B ZA200404584 B ZA 200404584B
- Authority
- ZA
- South Africa
- Prior art keywords
- composition
- compound
- surfactant
- solid
- solubilizer
- Prior art date
Links
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 title claims description 39
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 8
- 239000000203 mixture Substances 0.000 claims description 120
- 239000002775 capsule Substances 0.000 claims description 80
- 150000001875 compounds Chemical class 0.000 claims description 48
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 39
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 37
- 239000002552 dosage form Substances 0.000 claims description 36
- 239000007787 solid Substances 0.000 claims description 31
- 239000002904 solvent Substances 0.000 claims description 26
- -1 cyclobutyl- Chemical group 0.000 claims description 24
- 229920001223 polyethylene glycol Polymers 0.000 claims description 23
- 239000004094 surface-active agent Substances 0.000 claims description 21
- 238000000034 method Methods 0.000 claims description 20
- 239000002202 Polyethylene glycol Substances 0.000 claims description 19
- 239000003795 chemical substances by application Substances 0.000 claims description 17
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 16
- 239000002253 acid Substances 0.000 claims description 15
- 125000005456 glyceride group Chemical group 0.000 claims description 15
- 239000000126 substance Substances 0.000 claims description 15
- 239000004721 Polyphenylene oxide Substances 0.000 claims description 13
- 229920000570 polyether Polymers 0.000 claims description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 9
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 9
- 239000000194 fatty acid Substances 0.000 claims description 9
- 229930195729 fatty acid Natural products 0.000 claims description 9
- 230000002401 inhibitory effect Effects 0.000 claims description 9
- 229920006395 saturated elastomer Polymers 0.000 claims description 9
- 238000011282 treatment Methods 0.000 claims description 9
- 230000004614 tumor growth Effects 0.000 claims description 8
- 206010028980 Neoplasm Diseases 0.000 claims description 7
- 239000007788 liquid Substances 0.000 claims description 7
- 239000004698 Polyethylene Substances 0.000 claims description 5
- 201000011510 cancer Diseases 0.000 claims description 5
- 229920000573 polyethylene Polymers 0.000 claims description 5
- 150000005846 sugar alcohols Polymers 0.000 claims description 5
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical class CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 4
- 239000004359 castor oil Substances 0.000 claims description 4
- 235000019438 castor oil Nutrition 0.000 claims description 4
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 4
- 239000008158 vegetable oil Substances 0.000 claims description 4
- 230000001684 chronic effect Effects 0.000 claims description 3
- 230000002708 enhancing effect Effects 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 239000002480 mineral oil Substances 0.000 claims description 3
- 235000010446 mineral oil Nutrition 0.000 claims description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 3
- 238000002560 therapeutic procedure Methods 0.000 claims description 3
- 150000003626 triacylglycerols Chemical class 0.000 claims description 3
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 claims description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 2
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 claims description 2
- 235000019483 Peanut oil Nutrition 0.000 claims description 2
- 235000019486 Sunflower oil Nutrition 0.000 claims description 2
- 125000002933 cyclohexyloxy group Chemical group C1(CCCCC1)O* 0.000 claims description 2
- 150000004665 fatty acids Chemical class 0.000 claims description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- 235000010445 lecithin Nutrition 0.000 claims description 2
- 239000000787 lecithin Substances 0.000 claims description 2
- 229940067606 lecithin Drugs 0.000 claims description 2
- 239000004006 olive oil Substances 0.000 claims description 2
- 235000008390 olive oil Nutrition 0.000 claims description 2
- 230000036961 partial effect Effects 0.000 claims description 2
- 239000000312 peanut oil Substances 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- 239000002600 sunflower oil Substances 0.000 claims description 2
- 208000006332 Choriocarcinoma Diseases 0.000 claims 2
- 208000017604 Hodgkin disease Diseases 0.000 claims 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 208000034578 Multiple myelomas Diseases 0.000 claims 2
- 206010029260 Neuroblastoma Diseases 0.000 claims 2
- 206010039491 Sarcoma Diseases 0.000 claims 2
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 2
- 206010057644 Testis cancer Diseases 0.000 claims 2
- 208000008383 Wilms tumor Diseases 0.000 claims 2
- 230000001154 acute effect Effects 0.000 claims 2
- 210000004556 brain Anatomy 0.000 claims 2
- 210000000481 breast Anatomy 0.000 claims 2
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 2
- 210000001072 colon Anatomy 0.000 claims 2
- 210000003734 kidney Anatomy 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 230000002611 ovarian Effects 0.000 claims 2
- 210000002307 prostate Anatomy 0.000 claims 2
- 210000002784 stomach Anatomy 0.000 claims 2
- 201000003120 testicular cancer Diseases 0.000 claims 2
- 150000002148 esters Chemical class 0.000 claims 1
- 150000004667 medium chain fatty acids Chemical class 0.000 claims 1
- 239000003549 soybean oil Substances 0.000 claims 1
- 235000012424 soybean oil Nutrition 0.000 claims 1
- 150000003890 succinate salts Chemical class 0.000 claims 1
- 239000000243 solution Substances 0.000 description 63
- 239000003814 drug Substances 0.000 description 40
- 229940125890 compound Ia Drugs 0.000 description 38
- 229940079593 drug Drugs 0.000 description 37
- 238000009472 formulation Methods 0.000 description 30
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 25
- 241000282472 Canis lupus familiaris Species 0.000 description 19
- 229940123237 Taxane Drugs 0.000 description 16
- 238000004090 dissolution Methods 0.000 description 16
- 239000007903 gelatin capsule Substances 0.000 description 16
- 239000004615 ingredient Substances 0.000 description 16
- 229960001592 paclitaxel Drugs 0.000 description 15
- 229930012538 Paclitaxel Natural products 0.000 description 14
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 14
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 12
- 229920002534 Polyethylene Glycol 1450 Polymers 0.000 description 11
- 238000010521 absorption reaction Methods 0.000 description 11
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 10
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 10
- 238000003860 storage Methods 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- 239000012535 impurity Substances 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- 239000008380 degradant Substances 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 7
- 229930105110 Cyclosporin A Natural products 0.000 description 7
- 108010036949 Cyclosporine Proteins 0.000 description 7
- AOBORMOPSGHCAX-UHFFFAOYSA-N Tocophersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-UHFFFAOYSA-N 0.000 description 7
- 229960001265 ciclosporin Drugs 0.000 description 7
- 230000014759 maintenance of location Effects 0.000 description 7
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 6
- 229930003427 Vitamin E Natural products 0.000 description 6
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 6
- 230000007774 longterm Effects 0.000 description 6
- 239000008389 polyethoxylated castor oil Substances 0.000 description 6
- 229920000136 polysorbate Polymers 0.000 description 6
- 235000019165 vitamin E Nutrition 0.000 description 6
- 239000011709 vitamin E Substances 0.000 description 6
- 229940046009 vitamin E Drugs 0.000 description 6
- HTSGKJQDMSTCGS-UHFFFAOYSA-N 1,4-bis(4-chlorophenyl)-2-(4-methylphenyl)sulfonylbutane-1,4-dione Chemical compound C1=CC(C)=CC=C1S(=O)(=O)C(C(=O)C=1C=CC(Cl)=CC=1)CC(=O)C1=CC=C(Cl)C=C1 HTSGKJQDMSTCGS-UHFFFAOYSA-N 0.000 description 5
- TWJNQYPJQDRXPH-UHFFFAOYSA-N 2-cyanobenzohydrazide Chemical compound NNC(=O)C1=CC=CC=C1C#N TWJNQYPJQDRXPH-UHFFFAOYSA-N 0.000 description 5
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 5
- 235000021360 Myristic acid Nutrition 0.000 description 5
- TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Natural products CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 5
- 235000021314 Palmitic acid Nutrition 0.000 description 5
- 235000021355 Stearic acid Nutrition 0.000 description 5
- 239000002246 antineoplastic agent Substances 0.000 description 5
- 239000007857 degradation product Substances 0.000 description 5
- 229960003668 docetaxel Drugs 0.000 description 5
- 239000011159 matrix material Substances 0.000 description 5
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 5
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 5
- 229960002446 octanoic acid Drugs 0.000 description 5
- 238000003305 oral gavage Methods 0.000 description 5
- 229920002523 polyethylene Glycol 1000 Polymers 0.000 description 5
- 229940100474 polyethylene glycol 1450 Drugs 0.000 description 5
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 5
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 5
- 229920000053 polysorbate 80 Polymers 0.000 description 5
- 239000003381 stabilizer Substances 0.000 description 5
- 239000008117 stearic acid Substances 0.000 description 5
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 5
- JVKUCNQGESRUCL-UHFFFAOYSA-N 2-Hydroxyethyl 12-hydroxyoctadecanoate Chemical compound CCCCCCC(O)CCCCCCCCCCC(=O)OCCO JVKUCNQGESRUCL-UHFFFAOYSA-N 0.000 description 4
- 229920002562 Polyethylene Glycol 3350 Polymers 0.000 description 4
- 229920001304 Solutol HS 15 Polymers 0.000 description 4
- 238000007127 saponification reaction Methods 0.000 description 4
- 230000006641 stabilisation Effects 0.000 description 4
- 238000011105 stabilization Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- OIQOAYVCKAHSEJ-UHFFFAOYSA-N 2-[2,3-bis(2-hydroxyethoxy)propoxy]ethanol;hexadecanoic acid;octadecanoic acid Chemical compound OCCOCC(OCCO)COCCO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O OIQOAYVCKAHSEJ-UHFFFAOYSA-N 0.000 description 3
- MQFYRUGXOJAUQK-UHFFFAOYSA-N 2-[2-[2-(2-octadecanoyloxyethoxy)ethoxy]ethoxy]ethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCOCCOCCOCCOC(=O)CCCCCCCCCCCCCCCCC MQFYRUGXOJAUQK-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 238000010268 HPLC based assay Methods 0.000 description 3
- 229920002685 Polyoxyl 35CastorOil Polymers 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 231100000433 cytotoxic Toxicity 0.000 description 3
- 230000001472 cytotoxic effect Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 238000005342 ion exchange Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- QUANRIQJNFHVEU-UHFFFAOYSA-N oxirane;propane-1,2,3-triol Chemical compound C1CO1.OCC(O)CO QUANRIQJNFHVEU-UHFFFAOYSA-N 0.000 description 3
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 238000006136 alcoholysis reaction Methods 0.000 description 2
- 239000012736 aqueous medium Substances 0.000 description 2
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 2
- 239000007963 capsule composition Substances 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 229930182912 cyclosporin Natural products 0.000 description 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 2
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 239000012456 homogeneous solution Substances 0.000 description 2
- 229940072106 hydroxystearate Drugs 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 239000000693 micelle Substances 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000012959 renal replacement therapy Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000007928 solubilization Effects 0.000 description 2
- 238000005063 solubilization Methods 0.000 description 2
- 238000012430 stability testing Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 150000003628 tricarboxylic acids Chemical class 0.000 description 2
- WLWNRAWQDZRXMB-YLFCFFPRSA-N (2r,3r,4r,5s)-n,3,4,5-tetrahydroxy-1-(4-phenoxyphenyl)sulfonylpiperidine-2-carboxamide Chemical compound ONC(=O)[C@H]1[C@@H](O)[C@H](O)[C@@H](O)CN1S(=O)(=O)C(C=C1)=CC=C1OC1=CC=CC=C1 WLWNRAWQDZRXMB-YLFCFFPRSA-N 0.000 description 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- XRMDCWJNPDVAFI-UHFFFAOYSA-N 2,2,6,6-tetramethyl-1-oxopiperidin-1-ium-4-ol Chemical compound CC1(C)CC(O)CC(C)(C)[N+]1=O XRMDCWJNPDVAFI-UHFFFAOYSA-N 0.000 description 1
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 1
- 108010036941 Cyclosporins Proteins 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 101000656751 Haloarcula marismortui (strain ATCC 43049 / DSM 3752 / JCM 8966 / VKM B-1809) 30S ribosomal protein S24e Proteins 0.000 description 1
- 206010065042 Immune reconstitution inflammatory syndrome Diseases 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 229920002556 Polyethylene Glycol 300 Polymers 0.000 description 1
- 229920002675 Polyoxyl Polymers 0.000 description 1
- 229920002701 Polyoxyl 40 Stearate Polymers 0.000 description 1
- 244000191761 Sida cordifolia Species 0.000 description 1
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- LWZFANDGMFTDAV-BURFUSLBSA-N [(2r)-2-[(2r,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O LWZFANDGMFTDAV-BURFUSLBSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 230000001772 anti-angiogenic effect Effects 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920003086 cellulose ether Polymers 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 150000005690 diesters Chemical class 0.000 description 1
- 229930004069 diterpene Natural products 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 231100000682 maximum tolerated dose Toxicity 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- CXHHBNMLPJOKQD-UHFFFAOYSA-M methyl carbonate Chemical compound COC([O-])=O CXHHBNMLPJOKQD-UHFFFAOYSA-M 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 239000008203 oral pharmaceutical composition Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229940100460 peg-100 stearate Drugs 0.000 description 1
- 229940077414 peg-12 stearate Drugs 0.000 description 1
- 229940032067 peg-20 stearate Drugs 0.000 description 1
- 229940119517 peg-6 stearate Drugs 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920001992 poloxamer 407 Polymers 0.000 description 1
- 229920000059 polyethylene glycol stearate Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
- 229940099429 polyoxyl 40 stearate Drugs 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- GHBFNMLVSPCDGN-UHFFFAOYSA-N rac-1-monooctanoylglycerol Chemical compound CCCCCCCC(=O)OCC(O)CO GHBFNMLVSPCDGN-UHFFFAOYSA-N 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 239000008299 semisolid dosage form Substances 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 229950006451 sorbitan laurate Drugs 0.000 description 1
- 235000011067 sorbitan monolaureate Nutrition 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 229950004959 sorbitan oleate Drugs 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 150000003900 succinic acid esters Chemical class 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229940063683 taxotere Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical class OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Epoxy Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Description
a é
N Wo 03/053350 PCT/US02/40127 ®
PHARMACEUTICAL COMPOSITIONS OF ORALLY ACTIVE
TAXANE DERIVATIVES HAVING ENHANCED BIOAVAILABILITY
The present invention relates to pharmaceutical : compositions of orally effective taxane derivatives and to their use for inhibiting tumor growth in mammalian. hosts. The compositions of the invention enable the N production of dosage units that afford sufficient and consistent absorption of the taxane derivative, thereby providing safe and effective antitumor treatment.
Taxanes are diterpene compounds having demonstrated antineoplastic activity. Taxanes such as paclitaxel (Taxol?) and docetaxel (Taxotere’) , a semi-synthetic analog of paclitaxel, are clinically useful antitumor agents which impart a cytotoxic effect in vivo by a mechanism involving abnormal polymerization of tubulin and disruption of mitosis.
These agents are commercially available in formulations adapted for intravenous administration. The antitumor activity of taxanes is highly schedule dependent, and can be enhanced by prolonged exposure of tumors to the antitumor agents. Oral dosing of taxanes is a strategy that is being pursued to fully exploit the potential therapeutic advantages afforded by this route |,
i y of administration. These treatment regimens could include prolonged treatment at or near the maximum tolerated dose to maximize the cytotoxic effect, and chronic metronomic dosing below the maximum tolerated 0 dose to synergistically utilize the anti-angiogenic properties of the drug, while maintaining some cytotoxic effect and possibly reduce the occurrence of drug resistance in the tumors.
Because a number of studies have shown that the oral activity of paclitaxel is essentially nil, methods for administering taxanes in the presence of modulators have been investigated as a means of increasing the amount of taxanes in the plasma after oral administration. The literature provides reports of increases in systemic exposures of paclitaxel and docetaxel following oral administration of these antitumor agents as their intravenous solution formulations co-administered with known (pgp) efflux inhibitors, such as cyclosporin A (S.
Broder, et al, U.S. Patent 5,968,972, Oct. 19, 1899; J.V.
Asperen et al, “Enhanced Oral Absorption and Decreased
Elimination of Paclitaxel in mice Cotreated with
Cyclosporin A”, Clinical Cancer Research, Oct. 1998, Vol. 4, 2293-2297; J.M. Terwogt, et al, Lancet, "“Co-
Administration of cyclosporin enables oral therapy with paclitaxel”, 1998, Vol. 352, pg 285; J.M. Terwogt et al,
Clinical Cancer Research, “Co-Administration of Oral
Cyclosporin A Enables Oral Therapy with Paclitaxel”, Nov. 1999, Vol. 5, pg 3379-3384; C.D. Britten et al, “Oral -2-
fay C8 ® Paclitaxel and Concurrent Cyclosporin A : Targeting
Clinically Relevant Systemic Exposure to Paclitaxel”,
Sept. 2000, Vol. 6, pg 3459-3468; L.J. Denis et al, “Bioavailability of Oral Paclitaxel and Concurrent
Cyclosporin A : A Dose Escalation and Feasibility Study”,
Proceedings of the American Society of Clinical
Oncologists, 35 Annual Meeting, May 15-18, 1999; M.M.
Malingre, et al, “Clinical Pharmacology of Oral
Paclitaxel in a Dose Escalating Study”, Proceedings of the American Society of Clinical Oncologists, 35%" Annual
Meeting, May 15-18, 1999; D.J. Richel et al, “Cyclosporin A Strongly Enhances the Oral Bioavailability of Docetaxel in Cancer Patients”, Proceedings of the
American Society of Clinical Oncologists, 35% Annual
Meeting, May 15-18, 1999). See also published international patent application WO 98/53811 of Baker
Norton Pharmaceuticals, Inc. These modulator-containing formulations may also include a solvent, e.g. a } polyalkoxylated castor oil, as described in published international patent applications WO 97/15269 and WO 01/30448, both of Baker Norton Pharmaceuticals, Inc.
Although reports involving human clinical trials presented plasma levels of taxanes orally dosed in this manner, several disadvantages of this method of dosing were also described, including unpleasant taste, emesis, high interpatient variability, and non-linear response in absorption versus dose.
i >
A desire for increased bioavilability of taxanes upon oral administration, while avoiding the above-noted drawbacks of modulators such as cyclosporins, provided a stimulus for the preparation of orally-effective analogs.
One such class of taxane analogs is disclosed in WO 01/56565. The taxane analogs described in WO 01/56565, having the general formula I, shown below, display a significant inhibitory effect with regard to abnormal cell proliferation and have therapeutic properties that make it possible to treat patients who have pathological conditions associated with an abnormal cell proliferation. In addition, these compounds possess significant oral bicavailability, and thus can elicit their positive therapeutic affects after oral administration.
Oral pharmaceutical compositions containing taxanes (e.g. paclitaxel or docetaxel) at least 30 weight % of a . taxane carrier, having an hydrophile/lipophile balance (HLB) of at least about 10, and 0-70 weight % of a viscosity reducing co-solubilizer are disclosed in published international application WO 00/78247 of Baker
Norton Pharmaceuticals, Inc.
The development and therapeutic usefulness of such orally active taxane analogs as antitumor agents depends to a large extent on the attainment of formulations that provide not only suitable oral bioavailability, but also acceptable inter- and intra-patient variability in the extent of absorption. Parameters affecting the ‘
A Wo 03/0533350 : PCT/US02/40127 ® bioavailability of a drug following oral administration include water solubility, drug absorption in the GI tract, and first-pass effect. In the case of drugs having poor aqueous solubility, such as paclitaxel and docetaxel, drug absorption is often dissolution rate- limited and, therefore, dosage forms in which the drug is solubilized typically provide the best oral : bicavailability. However, it is generally preferred to have a solid dosage form for improved patient compliance, taste masking and other factors.
Thus, there exists an unmet need for chemically and physically stable dosage forms of orally effective taxanes, and especially solid dosage units, ‘which allow: for convenient dosing and which afford effective and . consistent oral absorption.
According to one aspect of the present invention, there is provided a pharmaceutical composition comprising an antitumor effective amount of an orally-active taxane derivative of Formula I or II:
t r
R' R2 ®
N\ 0
NH lo]
AN g
R Y Oli. T on —Z
HO § H
BzO = 0 0)
J
0]
A
0} 0 o] fo]
Ww IT
NH y pw
H T H sattli|H
OH PF
HO § H
S N
° [e) Oo o wherein R is phenyl, isopropyl, or tert butyl, R! is -
C(O)RZ in which RZ is (CH3)3CO-, (CH3)3CCH,-, CH3(CH3)30- \ , cyclobutyl-, cyclohexyloxy, or (2-furyl), and R? is CHa
C(0)0-, and a pharmaceutically acceptable solubilizing agent for the taxane derivative of Formula I or II.
® The solubilizing agent preferably consists essentially of at least one of the following solubilizer compounds: (a) a polyether glycol, (b) a saturated or unsaturated polyglycolized glyceride, or (c) a solid amphiphilic surfactant and optionally, further includes (d) an alcohol other than a polyether glycol, (e) a fatty acid ester derivative of a polyhydric alcohol, (f) a surfactant other than (c), (9) a vegetable oil, and (h) a mineral oil, or a mixture of any of (d) - (h).
According to another aspect of this invention, there is provided a method of inhibiting tumor growth in a mammalian host which comprises administering to the host, preferably orally, a tumor-growth inhibiting amount of the above-described composition.
As will appear from the examples provided below, the pharmaceutical compositions of the invention, which include both solution and encapsulated semi-solid dosage forms of a taxane derivative of Formula I or II, above, are pharmaceutically acceptable, chemically and physically stable and provide effective and consistent oral absorption.
The preparation of the compounds of Formula I, above, is set forth in detail, along with the manner of using such compounds as antitumor agents, in WO 01/56565.
The Formula II compound is also well known to those skilled in the art. oo : -7-
Preferred embodiments of the compounds of Formula ® including their pharmaceutically acceptable salts, are set forth in Table 1.
TABLE 1: Orally Active C-4 Methyl Carbonate Taxanes
EE LN LN CA
Among the compounds listed in Table 1, or pharmaceutically acceptable salts thereof, particularly preferred, are Ia, If, Ij and Ik. Compound Ia, 3'-tert- butyl-3'-N-tert-butyloxycarbonyl-4-deacetyl-3'-dephenyl- 3'-N-debenzoyl-4-0O-methoxycarbonyl-paclitaxel, is the most preferred compound for use in practicing the present invention. -8- y
A Wo 03/053350 PCT/US02/40127 ® As previously described, several different types of solubilizers for the taxane derivatives of Formulas I and
II may be used for the solubulizing agent in the composition of the invention. Suitable polyether glycols include, without limitation, polyethylene glycol (PEG) and polypropylene glycol. Particularly preferred are
PEGs within the molecular weight range from 200-8, 000 (commercially available from Union Carbide and BASF, among others), which includes those that are liquid at room temperature (e.g. PEG 200-400) and those that are solid at room temperature (e.g. PEG 600-8, 000, and the like). Representative examples of useful saturated, polyglycolized glycerides include, without limitation,
Gelucire® 44/14, Gelucire® 50/13, Gelucire® 53/10 and the like, which are solid at room temperature; and Labrasol® and the like, which are liquid at room temperate (all available from Gattefosse Corp., Westwood, New Jersey).
Suitable unsaturated polyglycolized glycerides include oo Labrafil® M1944CS and the like (also available from
Gattefosse Corp.).
Saturated polyglycolized glycerides, such as
Gelucires®, are preferred for use in the composition of the invention. They are prepared by the alcoholysis reaction of natural oils with PEG. The saturated polyglycolized glycerides are mixtures of mono-, di- and tri-glycerides of long-chain (Cs to Cg) fatty acids and polyethylene glycol mono-, di-esters obtained either by partial alcoholysis of hydrogenated vegetable oils using polyethylene glycol of relative molecular weight ranging from 200-2000 (predominantly 1500), or by esterification of saturated fatty acids using polyethylene glycol of relative molecular weight ranging from 200-2000 (predominantly 1500) with glycerol. Gelucires® are amphiphilic materials that are surface active and disperse in aqueous media to form micelles, microscopic globules or vesicles in which the incorporated drug is protected from macroprecipitation during contact with an aqueous environment such as the GI tract.
Gelucires® are identified by their melting point/HLB value, with higher HLB‘’s indicating greater water solubility. The preferred saturated polyglycolized glycerides are further characterized as follows:
® | Gelucire® 35/10 value
KOH/g) : cooitien composition
Caprylic acid 1-7% (nominally, 2.1%)
Capric acid 1-7% (nominally, 2.2%)
Lauric acid 31-41% (nominally, 35.4%)
EA
Myristic acid 7-17% (nominally, 12.9%) ore [re————
Palmitic acid 12-22% (nominally, 20.7%)
ES
Stearic acid 23-33% (nominally, 26.2%) mr
Gelucire® 44/14 ®
Saponification 76-90 mg KOH/g
Cowsattis composition
Caprylic acid 4-10% —
Myristic acid 14-24%
EA
Palmitic acid 4-14%
EE
Stearic acid 5-15%
EEA
® Gelucire® 46/07
Hydroxyl value 65-85 — (nominally, 70 mg
Saponification 126-140 mg KOH/g (nominally, 139 mg [Ea I composition
Caprylic acid <3% (nominally, <0.1%)
Ei
Myristic acid <5% (nominally, 1.4%) rr
Palmitic acid 40-50% (nominally, 44%)
I i
Stearic acid 48-58% (nominally, 52.8%)
Ea y
Gelucire® 50/13 ®
Hydroxyl value 36-56 mg KOH/g (nominally, 52 mg roe reer
Saponification 67-81 mg KOH/g (nominally, 74 mg
Et composition
Caprylic acid <3% (nominally, 0.2%) a prom <3% (nominally, 0.2%)
Myristic acid <5% (nominally, 1.8%) mr
Palmitic acid 40-50% (nominally, 42.5%) or rr———
Stearic acid 48-58% (nominally, 52.6%)
Ei
C Gelucire® 53/10
Hydroxyl value 25-45 mg KOH/g (nominally, 35 mg rr
Saponification 98-112 mg KOH/g (nominally, 104 mg omit 1 composition
Caprylic acid <3% (nominally, <0.1%) i
Myristic acid: <5% (nominally, 1.0%)
El
Palmitic acid 40-50% (nominally, 43%)
Stearic acid 48-58% (nominally, 54.2%) or rr
The choice in selecting the type(s) of Gelucire® to use in the composition of this invention is based on factors such as desired drug solubilization/loading and release profile. One of the more preferred saturated, polyglycolized glycerides for use in incorporating the taxane derivative in a semisolid matrix for encapsulation . is Gelucire 44/14, which provides suitable solubilization of the taxane and immediate/rapid release and dissolution in aqueous media. The use of other grades of Gelucire, or combinations of Gelucire’s with different properties,
could be utilized to modify the release and dissolution ® patterns to achieve more sustained delivery of the taxanes with less frequent dosing.
The solid, amphiphilic surfactants used in the practice of this invention are solid at room temperature and are characterized by having hydrophobic and hydrophilic components which impart surface activity to form micelles in which the incorporated drug is protected from macroprecipitation during contact with an aqueous environment such as the GI tract. Preferred solid, amphiphilic surfactants include, without limitation, those selected from the group of hydroxy-substituted stearic acid esters of polyethylene glycol, such as polyethylene glycol 660 1l2-hydroxystearate (available from BASF Corp., Ludwigshafen, Germany, as Solutol® HS15) and o-tocopheryl-polyethylene succinate esters of polyethylene glycol, also known as PEGylated o- tocopherol derivatives, such as polyethylene glycol-1000- succinate (available from Eastman Chemical Co.,
Kingsport, Tennessee as TPGS 1000).
Included among the optional components of the solubilizing agent are: an alcohol other than a polyether glycol, such as the monohydric alcohols ethanol, 2- (2-ethoxyethoxy) ethanol (Transcutol®, available from Gattefosse Corp.) and benzylalcohol, as well as the monomeric, polyhydric alcohols propylyene glycol, glycerol and the like; fatty acid ester derivatives of polyhydric alcohols, such as medium chain
® fatty acid monoglycerides, diglycerides (e.g. Capmul MCM, available from Abitech Corp., Janesville, WI), triglycerides and mixtures thereof (e.g. Miglyol® 808,
Miglyol® 810, Miglyol® 812, Miglyol® 818 and the like; : 5 available from Sasol Chemical Industries - North America, -
Cranford, NJ; surfactants other than the aforementioned solid, amphiphilic surfactants, such as those selected from the group of polyoxyethlene castor oil derivatives (e.g. polyoxyethyleneglyceroltriricinoleate or polyoxyl 35 castor oil or Cremophor®EL, polyoxyethyleneglyceroloxystearate or polyethyleneglycol 40 hydrogenated castor oil or Cremophor®RH 40, polyethyleneglycol 60 hydrogenated castor oil or
Cremophor®RH 60, and the like; (available from BASF
Corp., Ludwigshafen, Germany), polyoxyethlene derivatives of fatty acid partial esters of sorbitan, e.g. polyoxyethylene 20 sorbitan monolaurate or Tween®20, polyoxyethylene 40 sorbitan monopalmitate or Tween®40, polyoxyethylene 60 sorbitan monostearate or Tween®60, polyoxyethylene 80 sorbitan monooleate or Tween®80, and the like, polyoxyalkylene derivatives of propylene glycol which are in the form of block copolymers, e.g. Polaxamer 182LF or Pluronic® F62, Polaxamer 188 or Pluronic® Fé8, ~ Polaxamer 338 or Pluronic® F108, Polaxamer 407 or
Pluronic® F127, and the like (available from BASF Corp.,
Ludwigshafen, Germany), polyoxyethylene glycol stearates, e.g. PEG-6 stearate, PEG-8 stearate, polyoxyl 40 stearate
NF, polyoxyethyl 50 stearate NF, PEG-12 stearate, PEG-20 stearate, PEG-100 stearate, PEG-12 distearate, PEG-32 distearate, PEG-150 distearate and the like, sorbitan fatty acid esters, e.g. sorbitan laurate, sorbitan oleate, sorbitain palmitate, sorbiatan stearate and the ~ 5 like, and lecithin; vegetable oils, for example, soybean 0il, olive oil, peanut oil and sunflower oil; and mineral oil. : The pharmaceutical compositions described herein may be prepared in various dosage forms, including both solutions and encapsulated solids or semi-solid forms, as exemplified below. Solutions may be encapsulated as semi-solid or solid matrices in capsules made from various materials including, without limitation, geletin, hydroxypropylmethylcellulose (HPMC), cellulose, methyl cellulose, starch and the like. The capsule materials may be either soft or hard. The resulting dosage forms are pharmaceutically acceptable, chemically and physically stable and provide effective and consistent absorption of the taxane derivative.
The choice of ingredients for the dosage forms is influenced primarily by the solubility of the taxane derivative in the component (s) that make(s) up the solubilizing agent. To avoid precipitation of the taxane derivative at typical long-term storage conditions (e.g., 5°C to 30°C), the concentration (or percent loading) of the taxane in various dosage form compositions is oo preferably kept below the saturation solubility (either at room temperature if dosage form is liquid at room
® temperature, or at the solution temperatures used to melt solid ingredients for dosage forms that are semi-solids at room temperature). Table 2 presents solubility of
Compound Ia in various composition components. In the © 5 case of encapsulated dosage units, the strength (mg of drug per capsule) can be controlled by either modifying the concentration of drug in the fill composition, or by holding the drug concentration constant and modifying the amount of composition filled into the capsule. Each dosage unit of the composition of the invention, irrespective of its physical form, typically contains an amount of the orally effective taxane derivative in the range of from about 2 to about 50.0 mg., with a range of about 5.0 to about 25.0 mg being preferred.
TABLE 2
Solubility of Crystalline Compound Ia in Various
Bioavailability Enhancing Agent Components
Vehicle (Temperature) Compound Ia Solubility
Water (24 + 3°C) ~ 0.007 mg/mL
Propylene Glycol (24 + 3°C) ~ 40 mg/mL
Polyethylene Glycol 400 (24 + 3°C) ~ 125 mg/mL
Polyethylene Glycol 1450 (70°C) ~ 70 mg/mL 75% Polyethylene Glycol 400/25% ~ 100 mg/mL
Tween 80 (24 1 3°C)
Gelucire 44/14 (50°C) ~ 30 mg/mL
TPGS 1000 [Vitamin E PEG 1000 ~ 25 mg/mL
Succinate] (50°C)
Solutol HS 15 (50°C) ~ B80 mg/mL 50% PEG 400/50% Gelucire 44/14 ~ 80 mg/mL (50°0) 50% PEG 400/50% TPGS 1000 (50°C) ~ 80 mg/mL 25% PEG 400/25% PEG 1450/50% ~ 80 mg/mL
Gelucire 44/14 (60°C) 25% PEG 400/25% PEG 1450/50% TPGS ~ 80 mg/mL 1000 (60°C) 25% PEG 400/25% PEG 1450/50% Tween ~ 80 mg/mL 80 (60°C) 28% PEG 400/56% PEG 1450/12% Tween ~ 80 mg/mL 80 (60°C) 50% PEG 1450/50% Gelucire 44/14 ~ 70 mg/mL (70°C) 50-90% PEG 1450/Tween 80 (70°C) ~ 70 mg/mL 50% PEG 3350/50% Gelucire 44/14 ~ 60 mg/mL (70°C) 50-90% PEG 3350/Tween 80 (70°C) ~ 60 mg/mL 50% PEG 4000/50% Gelucire 44/14 ~ 60 mg/mL (70°C) 50-90% PEG 4000/Tween 80 (70°C) ~ 60 mg/mL
Ce, ® The taxane derivative is present in the dosage form at about 1 to 20% by weight, preferably about 4 to 10% by weight. In preferred compositions, one or more polyether : glycol solubilizer compounds of various averade molecular weights (for example PEG 300, -PEG 400, PEG 1450, PEG 3350, and the like) is present in the dosage forms at amounts totaling, by weight, of about 10% to about 99%, preferably about 15% to about 60%. In addition to, or in place of the polyethylene glycol, one or more polyglycolized glyceride solubilizer compounds having amphiphilic properties, such as Gelucire® 44/14,
Gelucire® 50/13, Gelucire® 53/10, and the like, can be present in the dosage forms at amounts totaling, by weight, about 10% to about 99%, preferably about 15% to about 60%. In addition to, or in place of the polyether glycol and polyglycolized glyceride, one or more solid, amphiphilic surfactant (s), such as Solutol HS 15 (i.e., polyethylene glycol 660 1l2-hydroxystearate or Polyoxyl- 15-hydroxystearate) and/or PEGylated a-tocopherol derivative, such as TPGS 1000 (i.e., vitamin E polyethylene glycol-1000-succinate or Vitamin E PEG 1000 succinate) can be present in the dosage forms at amounts totaling, by weight, about 10% to about 99%, preferably about 15% to about 60%.
The preferred compositions may also include one or more other surfactants, such as the polyoxyethylene castor oil derivatives (for example, polyoxyethyleneglycerol triricinoleate or polyoxyl 35 :
castor oil or Cremophor®EL, and the like), and/or sorbitan derivatives (for example, polyoxyethylene 80 sorbitan monooleate or Tween®80, and the like) and/or polyoxyethylene -polyoxypropylene glycol block copolymers (for example Polaxamer 182LF or Pluronic® F62, and the like) at amounts totaling about 5-25%.
Compositions embodying the present invention, as - will be seen in the examples provided below, substantially increase absorption of the orally effective taxane derivatives of Formula I and II, compared to the taxane derivative itself, and exhibit relatively low interpatient and intrapatient variability in the extent of absorption.
The dosage forms may optionally contain a pharmaceutically acceptable acid for stabilization of the taxane derivative, including inorganic acids and organic mono-, di-, or tri-carboxylic acids. It has been unexpectedly found that the addition of an organic or inorganic acid to the various solution, semi-solid and solid compositions of Compound Ia can markedly increase the stability of the composition both in solution (either as a dosage form or prior to capsule filling) or as a semi-solid or solid formulation. The acid added to the dosage forms for stabilization of the taxane derivative can be any one or combination of pharmaceutically acceptable inorganic acids (for example: hydrochloric acid, and the like) or organic mono-, di-, or tri- carboxylic acids (for example: acetic acid, ascorbic
® acid, citric acid, methanesulfonic acid, tartaric acid, and the like). Specific examples of pharmaceutically acceptable acids that are suitable for this purpose and amounts of such acids that are effective for increasing the storage stability of Compound Ia are set forth herein below.
Other ingredients that may be present in the pharmaceutical compositions of the invention include, for example, the following:
A pharmaceutically acceptable antioxidant for stabilization of the taxane derivative (e.g., ascorbic acid, BHA, BHT, vitamin E, vitamin E PEG 1000 succinate, and the like).
At least one or more precipitation inhibitor such as the polyvinylpyrrolidinone (PVP or povidone) polymers of various molecular weights (e.g., polyvinylpyrrolidinone
K12-18, average MW 10,000, polyvinylpyrrolidinone K30-18, average MW 40,000, and the like); or water-soluble cellulose ether derivatives (e.g., hydroxy- propylcellulose, hydroxypropylmethylcellulose, and the like) .
Added water to improve the compatibility of the compositions with the hard or soft capsule shell thereby enhancing physical stability. The addition is particularly beneficial in the case of compositions contining polyethylene glycol which, for example, due to their hygroscopic nature (for example polyethylene) tend to extract water from the capsule shell.
Glycerin or another suitable plasticizer for ® promoting physical stability when encapsulated in a soft gelatin capsule.
Further details regarding the practice of this 6 invention are set forth in the following examples, which are provided for illustrative purposes only and are in no way intended to limit the invention.
® EXAMPLE 1 (Capsule)
Compound Ia was added to a batching vessel containing polyethylene glycol 400, pre-melted polyethylene glycol 1450 and pre-melted Gelucire 44/14 and mixed at about 65°C to dissolve the drug and give a solution at 4% by weight. The solution was filled into size #2, #1 and #0 gray, opaque hard gelatin capsule shells at 50, 125 and 625 mg amounts, respectively, to provide dosage forms at strengths of 2, 5 and 25 mg of the taxane derivative per capsule, respectively. Caps were placed on the filled capsule bodies after they were stored at room temperature for about 30-60 minutes to solidify the filled contents. The recommended storage condition for the capsules is 12 months at controlled room temperature of 15-25°C (59-77°F). The dosage forms exhibit high potency recovery, rapid dissolution, and maintain excellent chemical, physical and dissolution stability during long-term storage, including no evidence of drug crystallization in the semi-solid matrix.
Dissolution studies in water (in the absence of added surfactant) indicate the semi-solid matrix erodes to a very fine dispersion rather than a macroparticulate suspension. Capsules were administered to cancer patients in Phase I clinical studies to determine various in vivo parameters following oral dosing, such as safety and pharmacokinetic profiles across different dose ranges and schedules, including bioavailability, intra- and inter-patient variability. Absolute oral bioavailability was determined by co-administering a 50 mg dose (i.e., ® two 25 mg strength capsules) of the capsule formulation orally along with an intravenously administered 25 mg dose of a solution formulation of a **C-labeled form of the drug.
The absolute oral bioavailability (F) shown is the mean value from the pharmacokinetic profiles of six patients.
Based on comparable in vitro dissolution profiles of the 2 mg and 25 mg strength capsules of each formulation, the absolute oral bioavailability would be anticipated to be equivalent if 2 mg or 5 mg strength capsules were administered to provide the same dose (i.e., 25 2 mg strength capsule or ten 5-mg strength capsules to dose 50 mg total of Compound Ia). The same is true of the value measured for the coefficient of variation (c.v.) for the formulations of this Example 1, which was determined by dividing the mean value for absolute oral bioavailability into the standard deviation, then multiplying by 100 to express as a percentage.
_ -26 -
. © ’ i» .
B
Ingredient Amount % of Amount % of [Amount |% of (mg) Total {mg) Total (mg) Total per per per Capsule Capsule
Capsule
Compound Ta [Po uas0 [33.0 [24.0%] 30.0 [24.08 [150.0 [2.0%
Gelwive e471 | 24.0 48.05 | 60.0 | 480% [300.0 [46.0%
EXAMPLE 2 (Capsule)
Compound Ia was added to a batching vessel containing polyethylene glycol 400, Tween®80, and pre- melted polyethylene glycol 1450 and mixed at about 65°C to dissolve the drug and give a solution at 4% by weight.
The solution was filled into size #0 gray, opaque hard gelatin capsules at 625 mg to provide a dosage form at a strength of 25 mg of the taxane derivative per capsule.
Caps were placed on the filled capsule bodies after they were stored at room temperature for about 30-60 minutes to solidify the filled contents. The recommended storage condition for the capsules is 12 months at controlled room temperature of 15-25°C (59-77°F). The dosage form exhibits high potency recovery, rapid dissolution, and maintains excellent chemical, physical and dissolution stability during long-term storage, including no evidence of drug crystallization in the semi-solid matrix.
Dissolution studies in water (in the absence of added surfactant) indicate the semi-solid matrix erodes to a very fine dispersion rather than a macroparticulate suspension. Capsules were administered to cancer patients in Phase I clinical studies to determine various in vivo parameters following oral dosing, such as safety and pharmacokinetic profiles across different dose ranges and schedules, including bicavailability, intra- and inter-patient variability. Absolute oral bioavailability and coefficient of variations were determined as described above in Example 1. 1] Composition D
Ingredient Amount (mg) Percentage of Total per Capsule
Pharmacokinetics 7 (oral Bioavailability)
C.V. (Coefficient of Variation)
EXAMPLE 3 (Capsule)
Compound Ia was added to a batching vessel containing polyethylene glycol 400, pre-melted polyethylene glycol 1450 and pre-melted Gelucire® 44/14 and mixed at about 65°C to dissolve the drug and give a solution at 4%. by weight. - 28 -
I
Ce ® The solution was filled into size #1 gray, opaque hard gelatin capsules at 500 mg to provide a dosage form at a strength of 20 mg of the taxane derivative per capsule. Caps were placed on the filled capsule bodies after they were stored at room temperature for about 30- 60 minutes to solidify the filled contents. Capsules were dosed to each of 2 dogs at a dose of approximately 2 mg/kg and plasma samples were taken and analyzed for pharmacokinetic parameters including drug concentrations versus time. Absolute oral bicavailability and coefficient of variation were determined as described above in Example 1.
Composition E
Ingredient Amount (mg) Percentage of
Total
Compound 1a
GeTucize #4/14 220.0
Pharmacokinetics
F (Oral Bioavailability)
C.V. (Coefficient of Variation) ~
EXAMPLE 4 (Capsule)
Compound Ia was dissolved at 10% by weight in pre- melted Gelucire 44/14 at about 65°C and the solution was filled into size #1 gray, opaque hard gelatin capsules.
Caps were placed on the filled capsule bodies after they were stored at room temperature for about 30-60 minutes to solidify the filled contents. Capsules were dosed to each of 3 dogs at a dose of approximately 3 mg/kg and plasma samples were taken and analyzed for pharmacokinetic parameters including drug concentrations versus time. The AUC’s were calculated and used to determine the absolute oral bicavailability relative to
Compound Ia administered intravenously to dogs from a PEG 400 solution.
EXAMPLE 5 (Capsule)
Compound Ia was dissolved at 10% by weight in pre- melted Solutol HS 15 at about 65°C and the solution was filled into size #1 gray, opaque hard gelatin capsules.
Caps were placed on the filled capsules after they were stored at room temperature for about 30-60 minutes to solidify the filled contents. Capsules were dosed to each of 3 dogs at a dose of approximately 3 mg/kg and plasma samples were taken and analyzed for pharmaco- kinetic parameters including drug concentrations versus time. The AUC’s were calculated and used to determine the absolute oral bioavailability relative to Compound Ia -30 - gw
) . {» ® administered intravenously to dogs from a PEG 400 : solution.
Composition G
Ingredient Amount (mg) Percentage of Total
Compound 1s
Pharmacokinetics
CV. (Coefficient of Variation)
EXAMPLE 6 (Capsule)
Compound Ia was dissolved at 10% by weight in pre- melted TPGS 1000 (vitamin E PEG 1000 succinate) at about 65°C and the solution was filled into size #1 gray, opague hard gelatin capsules. Caps were placed on the filled capsule bodies after they were stored at room temperature for about 30-60 minutes to solidify the filled contents. Capsules were dosed to each of 3 dogs at a dose of approximately 3 mg/kg and plasma samples were taken and analyzed for pharmacokinetic parameters including drug concentrations versus time. The AUC's were calculated and used to determine the absolute oral bioavailability relative to Compound Ia administered intravenously to dogs from a PEG 400 solution.
mesiom | wwo we
IL IT
EXAMPLE 7 (Capsule)
Compound Ia was dissolved at 4% by weight in a combination of PEG 400 and pre-melted Gelucire® 44/14 at about 65°C and the solution was filled into size #1 gray, opaque hard gelatin capsules. Caps were placed on the filled capsule bodies after they were stored at room temperature for about 30-60 minutes to solidify the filled contents. Capsules were dosed to each of 3 dogs at a dose of approximately 2 mg/kg and plasma samples were taken and analyzed for pharmacokinetic parameters including drug concentrations versus time. The AUC’s were calculated and used to determine the absolute oral bioavailability relative to Compound Ia administered intravenously to dogs from a PEG 400 solution.
) Composition I
Ingredient Amount (mg) Percentage of Total
Compound Ta
Pharmacokinetics
EXAMPLE 8 (Capsule)
Compound Ia was dissolved at 4% by weight in a combination of PEG 400 and pre-melted TPGS 1000 (vitamin
E PEG 1000 succinate) at about 65°C and the solution was filled into size #1 gray, opaque hard gelatin capsules.
Caps were placed on the filled capsule bodies after they were stored at room temperature for about 30-60 minutes to solidify the filled contents. Capsules were administered to each of 3 dogs at a dose of approximately 2 mg/kg and plasma samples were taken and analyzed for pharmacokinetic parameters including drug concentrations versus time. The AUC’s were calculated and used to determine the absolute oral bicavailability relative to
Compound Ia administered intravenously to dogs from a PEG 400 solution.
Composition J
Ingredient |_Amount (mg) | Percentage of Total
Pharmacokinetics
F Toma] Slomallability) | may
CV. (Coefficient of Variation) | iv
EXAMPLE 9 (Solution)
Compound Ia was dissolved at 4 mg/mL in 75% PEG 400/25% Tween 80 (cleaned by passage through an ion exchange column) and the solution was administered by oral gavage to each of 3 dogs at a dose of approximately 2 mg/kg. Plasma samples were taken and analyzed for pharmacokinetic parameters including drug concentrations 4 versus time. The AUC'’s were calculated and used to determine the absolute oral bioavailability relative to
Compound Ia administered intravenously to dogs from a PEG 400 solution.
Composition K
Thgredient
Compound Ta som
PEG 400 | g.s. to 1.0 mL mekal | wom
Pharmacokinetics
F (Oral Bioavailability) 29.3%
C.V. (Coefficient of Variation)
® EXAMPLE 10 (Solution)
Compound Ia was dissolved at 6 mg/mL in PEG 400 and the solution was administered by oral gavage to each of 3 dogs at a dose of approximately 3 mg/kg. Plasma samples were taken and analyzed for pharmacokinetic parameters including drug concentrations versus time. The AUC’s were calculated and used to determine the absolute oral bioavailability relative to Compound Ia administered intravenously to dogs from a PEG 400 solution.
Composition L
Tngredient | Amowt
Compound To | Goma
PEG 400 _g.s. to 1.0 mL
Pharmacokinetic
F (Oral 15.6%
Bioavailability)
C.V. (Coefficient of 45%
Variation)
EXAMPLE 11 (Solution)
Compound Ia was dissolved at 6 mg/mL in Labrafil
M1944CS (an unsaturated polyglycolized glyceride) and the solution was administered by oral gavage to each of 3 dogs at a dose of approximately 3 mg/kg. Plasma samples were taken and analyzed for pharmacokinetic parameters .20 including drug concentrations versus time. The AUC'Ss were calculated and used to determine the absolute oral bioavailability relative to Compound Ia administered intravenously to dogs from a PEG 400 solution.
Composition M
Corpownd Ta [tows
Labrafil MIS42CS | as. 6 1.0 wi
Pharmacokinetics
F (Oral B.6% -Biocavailability)
C.V. (Coefficient of
Variation)
EXAMPLE 12 (Solution)
Seeds Se solution)
Compound Ia was dissolved at 4 mg/mL in 75% PEG 400/25% Cremophor EL (cleaned by passage through an ion exchange column) and the solution was administered by oral gavage to each of 3 dogs at a dose of approximately 2 mg/kg. Plasma samples were taken and analyzed for pharmacokinetic parameters including drug concentrations versus time. The AUC’s were calculated and used to determine the absolute oral bioavailability relative to
Compound Ia administered intravenously to dogs from a PEG 400 solution.
Composition N
Ingredient | mwount
Compound Ta | som]
Cremophor BL | 0.25mi
PEG 400 |__g.5. to 1.0 mL
Pharmacokinetics
F (Oral 7.5%
Bioavailability)
C.V. (Coefficient of 2%
Variation) i -36 -
@® | EXAMPLE 13 (Capsule)
Sera 10 \Lapsule)
Compound II was added to a batching vessel containing pre-melted Gelucire® 44/14 and mixed at about 65°C to dissolve the drug and give a solution at 20% w/w.
The solution was filled into size #1 gray, opaque hard gelatin capsules at 250 mg to provide a dosage form at a strength of 50 mg of Compound II per capsule. Caps were placed on the filled capsules after they were stored at room temperature for about 30-60 minutes to solidify the filled contents. The dosage form maintained rapid and full dissolution and excellent chemical and physical stability during long-term storage at 5 and 25°C.
TT comosition 5
Ingredient Amount Percentage of (mg) per Total
Capsule
Compound 11
Gelucire 44/14 | 200.0
Total 350.0
EXAMPLE 14 (Capsule) ®
Compound II was added to a batching vessel containing pre-melted Gelucire 44/14 and Cremophor EL (cleaned by passage through an ion exchange column) and mixed at about 65°C to dissolve the drug and give a solution at 20% w/w. The solution was filled into size #1 gray, opaque hard gelatin capsules at 250 mg to provide a dosage form at a strength of 50 mg of Compound
IT per capsule. Caps were placed on the filled capsules after they were stored at room temperature for about 30- 60 minutes to solidify the filled contents. The dosage form maintained rapid and full dissolution and excellent chemical and physical stability during long-term storage at 5 and 25°C. [TT composttim ®
Ingredient Amount Percentage of (mg) per Total
Capsule
Compound 11
Gelucire 44/14 150.0
Cremophor EL 20.0% [moral | son | wooies
EXAMPLE 15 (Capsule)
Compound II was added to a batching vessel containing pre-melted Gelucire® 44/14 and pre-melted
Solutol HS 15 and mixed at about 65°C to dissolve the drug and give a solution at 20% w/w. The solution was filled into size #1 gray, opaque hard gelatin capsules at 250 mg to provide a dosage form at a strength of 50 mg of
® Compound II per capsule. Caps were placed on the filled capsule bodies after they were stored at room temperature for about 30-60 minutes to solidify the filled contents.
The dosage form maintained rapid and full dissolution and excellent chemical and physical stability during long- term storage at 5 and 25°C. — Composition 0
Ingredient Amount Percentage of (mg) per Total 3 Capsule
Compound TT
GeTucive 44/13
SSTutel #5 15
EXAMPLE 16 (Capsule)
Compound Ig was added to a batching vegsel containing pre-melted Gelucire® 44/14 and mixed at about 65°C to dissolve the drug and give a solution at 10% w/w.
The solution was filled into size #1 gray, opaque hard gelatin capsules at 200 mg to provide a dosage form at a strength of 20 mg of Compound Ig per capsule. Caps were
Placed on the filled capsules after they were stored at room temperature for about 30-60 minutes to solidify the filled contents. The dosage form displayed rapid and full dissolution.
Ingredient Amount Percentage of (mg) per Total
Capsule
Corpouad 13
GeTucive 44/12 | 180.0
EXAMPLE 17 (Capsule)
Compound Ig was added to a batching vessel containing pre-melted PEG 1450 and mixed at about 65°C to dissolve the drug and give a solution at 10% w/w. The solution was filled into size #1 gray, opaque hard gelatin capsules at 200 mg to provide a dosage form at a strength of 20 mg of Compound Ig per capsule. Caps were placed on the filled capsules after they were stored at room temperature for about 30-60 minutes to solidify the filled contents. The dosage form displayed rapid and full dissolution.
I Composition §
Ingredient Amount Percentage of (mg) per Total
Capsule
Compound Tg oC "WO 03/053350 PCT/US02/40127 ® EXAMPLE 18 (Capsule)
Compound Ig was added to a batching vessel containing pre-melted PEG 3350 and mixed at about 65°C to dissolve the drug and give a solution at 10% w/w. The solution was filled into size #1 gray, opaque hard gelatin capsules at 200 mg to provide a dosage form at a strength of 20 mg of Compound Ig per capsule. Caps were placed on the filled capsules after they were stored at room temperature for about 30-60 minutes to solidify the filled contents. The dosage form displayed a modified release pattern with a slower dissolution rate to provide for a more sustained delivery of the drug.
Ea. ——
Ingredient Amount Percentage of
ETT
Capsule
EXAMPLE 19 (Solution)
Compound Ig was dissolved at 8 mg/mL in Labrasol and the solution was administered by oral gavage to each of 5 rats at a dose of approximately 15 mg/kg. Plasma samples were taken and analyzed for pharmacokinetic parameters including drug concentrations versus time. The AUC’s were calculated and used to determine the absolute oral bioavailability relative to Compound Ig administered intravenously to rats from a cremophor/ethanol/water solution. _ mredtene | mews
Compound Tg Tabrasol | gs to 1.0 wi]
Pharmacokinetics
F (Oral 14.1%
Bioavailability)
C.V. (Coefficient of 7.3%
Variation)
Acid-stabilized dosage forms of the present invention are described in the following examples:
EXAMPLE 20
Capsule formulations comprising Compound Ia, a solubulizing agent and an effective amount of a pharmaceutically acceptable acid stabilizer were prepared according to the following general procedure: 1. Add weighed amount of selected solubulizing agent component(s) (in liquid, powder, granular or pre- ‘melted molten form) to a batching vessel pre-equilibrated to approximately 70°C. 2. Begin stirring to completely melt any solid component (s) of the solubulizing agent at approximately 70°C to obtain a clear, homogeneous solution.
to "wo 03/053350 PCT/US02/40127 ® 3. Add weighed amount of stabilizer acid to the stirring solubulizing agent from step 2 and continue stirring at 70°C. 4. Continue stirring at approximately 70°C to completely mix and dissolve the acid stabilizer. 5. Slowly add weighed amount of Compound Ia to the stirring mixture of solubilizing agent and acid stabilizer from step 4 with continuous stirring at 70°C. 6. Continue stirring the mixture from step 5 at approximately 70°C to give a clear, homogeneous solution. 7. Fill an appropriate amount of the solution from step 6 into capsule shells to provide capsules of various dosage strengths. For formulation solutions having a taxane derivative content of 4 wt %, for example, 5 mg strength and 25 mg strength capsules are prepared by filling 125 mg and 625 mg of the formulation solutions into Size #1 (or #2) and Size #0 two-piece hard gelatin capsule shells, respectively. 8. Allow the contents of the capsules from step 7 to solidify.
S. Place the caps on the filled capsule bodies from step 8.
The Compound Ia potency and impurity/degradation product profile were evaluated and compared using the
HPLC assay methodology described immediately below. 1. The cap is removed from one or more capsules and the capsule(s) containing the semi-solid formulation contents are placed in a glass volumetric flask.
Acetonitrile is added to bring the flask to exact volume.
Typically, the number of capsules and volume of acetonitrile added are selected to achieve a final taxane derivative concentration of 0.25 mg/mL (e.g., one 25-mg strength capsule or five 5-mg strength capsules in a 100 mL volumetric flask, etc.) . : 2. The flask is sealed, placed in an ultrasonic bath, and the sample is sonicated for approximately 30 minutes, with periodic shaking of the flask, to completely dissolve and mix the formulation contents into the acetonitrile. 3. An aliquot of the solution is then assayed using the following gradient HPLC assay methodology : A 20 microliter aliquot of the sample is injected onto a (C18 reverse-phase HPLC column (YMC ODS-AQ, 150 mm length x 4.6 mm i.d4., 3 um particle size, 120A pore volume) and eluted using a gradient mobile phase system (shown below) at a solvent flow rate of 1.0 mL/minute for a 70 minute run time. During elution, the solution is continually exposed to ultraviolet light at a wavelength of 240 nm to detect the parent taxane derivative peak and associated impurity/degradant peaks. The signal generated from the absorbance of ultraviolet light by the component (s) present in the sample is converted from analog to digital and expressed as a peak in the chromatogram baseline signal monitored throughout the elution run time. The peak area is integrated using chromatography peak integration software. The amount of parent taxane :
® derivative present in the sample (typical peak retention time approximately 33 minutes) is quantified by comparing the peak area of the sample with that of a standard solution of drug prepared at known concentration. The amount of impurity/degradant present is reported as I.I. (impurity index), which is an estimate of the amount of an impurity/degradant present in a sample and is calculated from the ratio of the peak area of the impurity/degradant relative to the total peak area of all the sample components normalized by multiplying this ratio by 100. The I.I. is determined when the component is measured without comparison to standard and without correcting the peak area of the impurity/degradant for the relative response factor. The identity of unknown impurities/degradants is typically reported as their respective HPLC retention time in minutes, or by their
HPLC relative retention time (RRT, no units) which is the : retention time of the impurity/degradant peak relative to the retention time of the parent peak.
Gradient Elution Program
Time (minutes) Percent Percent Gradient Profile
Acetonitrile Water 4 as Iss TT isocratic] ie ses TT Ginear 3 |’ Tas | Tsocratic 59 | 80 TT H0 I tinear 62 [90 TT 50 | isocratic] [es es es fimear [70 as Se ¥eocraric
Table 3, below, shows the beneficial effect of various acids on the stabilization of Compound Ia- containing dosage formulations prepared according to the procedure described immediately above after seven (7) days at 70°C, as compared to formulations having no added acid. The formulations were prepared as a solution composed of 3 weight % Compound Ia; 84.9 weight % polyethylene glycol 1450; 12 weight % Tween® 80. ] - 46 - n
NENT .
I
Bn rf gy 9
Bg He je | [9 |e fo
H Ble [a [0 [2 fe [0 [0 j=4 wo oA
[0] [5 e 9 © oi
Hg in jo Joo | |H jon jin [©
CO A CLAN RAT A CR Lo Lal A
Mla o [0 |Jo |Jo |o |[o lo lo cH [UR Rel [1 NT} : a=) i lo
[1] ej NE a | id joo | j= Jo in Jo ols o Jon JH j~ Jv |H jo |m
Bs] mo NH Ja jo [an jo (+H jo
TlH [ol Rey]
HO oi] fm] [iT a ~|— oT 10 i= vo |o
D FEI FS)
HD uv |v
Hg No |0 | NN jn I~ Jo
S| © mo |v jo ld ln | jin of Le] to jo} 11}
E| © oO IQ |ajo jo jo jo jo
Hi on FER 3
Oo Oo |o 1s] 2 1a ™
Hl fo] = A |T (oO a © |T |v |v jo ja |n & REN REN NEEAL
A EE PP 0)
U «= Ju Jo
CREME REE LEEER EEE og fd flo [9 (R] [MH
I OIL Ig iH IO |g |= |”
Oo [Soe (PY |2 [av [+ << ole [81081813 |B = Mm > lg [a |= 9° go [9° [0° |B ~ a fe foe (FF
Rh a i I © . Jo jo oO
In Table 4, below, it can be seen that the beneficial effect obtained from the addition of citric acid to the basic formulation of Table 3 is maintained over a broad concentration of added acid.
This stability testing was performed after maintaining the solution, prepared and encapsulated as described immediately above, for a period of from one (1) to seven (7) days at 70°C.
Tw » an ® 0
SB j= ~ D5 © “lo |m o |v
Et EN KE ol ha 0 3 Of | |< 1 | : of
E ©
HA
: ™M . ] H= 0 ~| 5 o |< jin o oN | o 0
S |= jo — ~~ [— hort — og] © oO |o |o o oO jo =] o 8]
Oi 5 .
Hl © tA § ~
[1]
Df ~lu a [|e oo) ~ | — ™
S [8 Mm (I~ Jo i m |= + mM ol © o lo la o lo lo co Jo
H
Hl o
Q o aR [1M] fo] of lo)
Hae 1) a 0 is) 9)
NE © Jo |~ 0) ow | Te) — 5.8 — | {en J ~ |o o — ale lo |o |e A |o |e o |o
Hl ty ’ LD 0 : ol I=] = i . g
MH a < U (ou |v uv ju [vu uv |o [o] [o} [o] [eo] o [0] oO [o]
Mm [en] (a) oO oO [=] oOo Oo [en] a ~~ f= £~ ~ |~ ~ ~ > >1 ell Bal 2 5 | |& | 8 |oig | gO’
A IQA | (m} A [A fn] [a] 1 fn jr~ i Mm ir | i [3] (4) 4} rf | -d . i 5
Ei HT I |nwo < OU -A OA v 4] o 0° & oe = — o o —
As is evident from the data presented in Table 5, below, the addition of citric acid is effective for stabilizing various of the enhanced bicavailabilicy dosage formulations of orally-active taxane derivatives embodying the present invention. The formulations were prepared as solutions containing 3 weight % of Compound
Ia and 96.9 weight % of a solubilizing agent, with or without optional surfactant, and 0.1 weight % of citric acid. The solutions were prepared and encapsulated as described immediately above. The stability testing was performed after maintaining the solution for seven (7) days at 70°C. i -50-
® a ~ J > 5 :
HE ~~ ©w on 0 of ~ ~~ ~ nn rR-EA ~ ~~ it oN je = |= I=
Ugo
OE O®
BHA
= : 3 n |e © SE PN m [oo |o se el PEREEERRER 2) oo oo o oOo oo [=] o o o oo @
Q le}
Ld
ME ol ala le 0 |v In lo Jo joo lo alg 1° 1° = = mE
Gl E aq lo lo lo lo 0 |= Jo lo |o a
LY
= & mE 1 |5 ~ — oo ln l= 0 j= Jo |~ old 5 7 J CN LoS Lo SE LJ LS AJ A 3 f=! o co lo lo lo jlo Jo jo je 0|7 aj fat e © 00 oe oe be] - l= |e
Io} Le] o o o
M - ~ ~ ~ . o [é] : ft <t <i 1} Joe ae ae 0 op 9° ~ —t a
Qa BATE a RAVE bo’ B MT MEE RE CE
Z fo] . . . . . . <t <ft <t = o [=] o o o o <ft < <tf oe ~ |~ ~ ~ ~~ hell hg
J o oo o a [=] (=) o [0] a [0)] ol © | © © | © |o 4 H ul “ | x = - =r og |g ta 8 Is g [|= lo |o [Jo 0 lo Jo a 0} 9 Jo |= 3 3 a Ii] @ | 0 fu] a lo Jo + ~ 4
Pua gE & 1&8 (8 EERE A go {oe do oo foe ge fog foe Jeo Joe o oO oo oO oO o [o] <§ <t =f a BR ERERREER@ 1d ~ ~ ~ ~ ~ ~ ~~ ~ ~ ~~ o oO o oo oOo oo o o oo o [Tg] wn [59] un wn oo [ee] un un o a < |= < mm oc |o tm o a EE m mie le 0 | =
Hl o (o lo jo (vo lo jlo [© [8 [© = £3] 423] £3} = = | Ed 53} = [£3] [1 o1} is [a9 [1] fal} fA al} [=H [29 : go Jao Jao loo Joao foo foo Joo Jao Joe oo [=2} [e)Y (=) (=) (=) jon <t <tt <H in |e < joa |w [jf 0 |o © |~ Jo ~ Jo |~ Jo |= |= ~~ ~ ~ ~ ~~ ~~ ~ ~~ ~~ ~
[0] {uv} (W) [iv] © 1] © [iv] [ir] [1] [=] [=] H [=] Ih 1 H ~ = =
Lo] mole glo ojo ojo Slt TY TT T|T CT
EEE ER EE ER ER ER ERI ERI ER
[o} © <|0 «|0 <0 lo aj0 40 gO ]O
EI EAE
3 |8-Aald -xld-4]0-A|0-A)J0 lO -rH|O AO -~
O [0 ulo slo Lio HO 8lO LO H|O HO ~ b Do) wl HE} aE] Rl Ra BD a0 [00 [de [op {de -ri{d0 -ri[oP -—ijde -ri|op [de ™ Mm Ulm Ol Om Om Um Um On Om ©
The data presented in Table 6 demonstrate that the stability of Compound Ia in dosage formulations containing solubulizer compounds, such as polyethylene glycols, surfactants or the like which have residual levels of alkyl metals, is substantially enhanced by the addition of an acid stabilizer.
The dosage formulation solution, which contains 3 weight % of Compound Ia and varying amounts of the solubulizing agent, were prepared and encapsulated as described immediately above.
The stability tests on these formulations were conducted after three (3) days at 70°C (Table 6-1) and after seven (7) days at 70°C (Table 6-2). Good results were obtained with a citric acid addition of 0.1 wt %.
Ce \
HEN jo je
EER IF FI
4 0, bf ’ oE 0
HHA ) .
E .
CIT IT ER g
SE CA KE
2 ™ - [wi] wn [nd 2 aE . 8 © | =< IRIS 08 0 « “ &
HIS Ld) a} 3] fol}
SHE] :
Qa p 3 [URES =} M [r= § - ~| © un ~-
TG a J 0] § = 1 i —_ ned = oO eo] 8g : 8 8 3 [i)} -r [eo] [9)] ri
H 2 0% a 3
HE I s 9 Ww 5S, fe fa 0 5 § ® og
Lo] Bl — ™M —
So . . . al} - ™M ol) of f= «© o o ro] oO 2
Hig I= 0 ola eo} 197} ™M @ fo wn oo a ~ 8 5 ny 2 2 a ro) © n a J oN 2 a -r | tn jul or
H @ prs 2} oN ®) 0] 3 i | jo} v QL ES) [o]] oS = o [=] -r ~ a g [0] [0] a 0 | © [0] [®]
H a Q 9 Q + a ™ Q gE |& |& |& g Hd 2 = [eo] [U1 <ft . ae Joe Joe a0 &) + o <t 7 o =} =} o ~— o ~~ [=)} . - . . - Q oy I'y) 0 oN oy [a] [3] m OU fa)
Rl NE i N <> Bp od . [£3] HN tN 4 ra [eo] Q BE o a 1a a ra Te} fe) aH = [= = | D o o oO
Et | i= © To] a 2 l2 ja [2 TR : ' 4 i Oo
Am la a A = x 2 a foe glee Jor + & o lov gle =) Q s = a . RS] BN . . 3 32 | oc 9 0 8 |s8ls |Z mn © T° &© = Hog Ho << [oe] rf t [23g [25] L584 5 [393 [33 Ow 0 © XM o O wl}0 oy [£3] 0 [@) 0 =] E .|B E A 3 a
Oo Sd o}0o on Iz ° .
O Tilo Z|0o Blo J ul 0 A i \ er a i L-] 00 Ulae Ofde Uflee © aH = a . ‘ m &lm on Gm ® Mm m = Pr) « fo] [3] Lo] -H3-
8 ® ~ a heli] EF vo Jun [=~
FEES [4 5
Ooo
OE Q
BHQ o g
FI 2 I ht g —~|5 o o o Re oC | @ [1] a 0 © [0]
[0] iS)
ISN PE! 0 a= [oF
NH
2 (TC ™ n t=
G |S = a ls eX ol o aia ~- tn ~N — oJ ’ © - — ™m oN =} oy La] —
SIE ! ! g g o o o = -H -H viz QO ls : @ . +o g g 25 (oN 0, & oN
Vig =
Allg = ™ o
SP (ew) [= fal i ™ rr} 0 0
H a fo] - - of o lo © © =] a o ES] is]
H = la |o [© g 8
SEE SH a g 1g |I8 |8 ™ < © 2 18 18 |& S 4 le o |o j= |x > 3 ~~ ~~ 2 a | 13 Is No a a [a8 |R o 0 ™ I) ™ ™ = fo ™ ™ mm o o 2 182 [BIB nn a Ia (a A <r ™
Le] Lo) i ™ 2 jz l2deg lh hd ol 8 ® « ie Zo vjo v am
LR LIZERW o 0 0 4} . olg O
SSS 58a he hs: ald ol. o 9g aie ale lo Q Q
EN EE EAE H H
3 b=] Je] Wn © [1]
Q wiQ a2 2 &] U
SR FEES
0 o|0c]0 *jo « = ol
O Jjo Jj0 AHjO ~ to} eo}
Q 2] ~ =~ ord or do Oo olor oe = o a
MN VIM OM Hi H 5 5 . v ° -b4-
® WO 03/053350 PCT/US02/40127
EXAMPLE 21
Comparative testing was conducted to evaluate the effect of citric acid on stability (i.e, degradation - product levels) of certain preferred dosage formulations at the initial timepoint, as determined by characterizing the degradation product profile using the gradient HPLC assay methodology, described above. The formulations tested contained 4 wt% of Compound Ia, solubilizing agents of varying composition, and either 0.1 wt% of citric acid of no added citric acid, as a basis of comparison. The formulations were prepared according to the general procedure described in Example 20, and filled into #0 capsules. As shown in Table 7, at the initial timepoint, the formulations containing 0.1% citric acid display higher Compound Ia potency (i.e., area percent of the peak with relative retention time of 1.00), and much lower levels of degradation products, particularly at
RRTs 0.18/0.19, 0.30-0.33, 0.39/0.40, 0.66 and 1.42-1.52) compared to counterpart formulations without citric acid.
Furthermore, after 15 months storage at 25°C, the formulations containing 0.1% citric acid continue to display higher Compound Ia potency (i.e., area percent of the peak with relative retention time of 1.00), and lower total levels of degradation products compared to counterpart formulations without citric acid at the initial timepoint. All of the empty spaces in the table indicate the degradant was not formed, or was below the limit of detection (i.e., about 0.05 peak area percent).
3 co ha <t+ ho wv, . gal (© = 2 ol IE 3 153 -— [=~] [=] — fe) — ol 0 & S — < = 0 -
ES
— g = BA BREE mje I] peal =) arop feof fafel Ie] fale
ON: [= YB oC [= 4 B=) Ey bo) : = = EER ENEN NEN BE EEN EN =| I] Sl IE 21 IRR
E
— - = R I P2A g 32° -3 =
Bt ~ oo oo
ERIE: = — = S S 3 2 | 8 © = = =) =) =) oS
Q a0, x] Q [0
BE Il fel
T [31°C - 2 8 ~ \G oo <> vy - = 0 o & [3 8 a 3 [9 od EE Sl |= BE 8 g = oS < =] NS) ~ < a] < IS < ~ < < = &8) S . |dlze 3 3 5 7 5 - Bins < IS < < = = = a l® = | § ] |2ls po 5! = 7] Ba oo " | 8 = 2 Qo “ = 3 2 8 2 |gl=° = © Sx o nn <r ND «@ won 5 |=8%] 9] |= gl =| Igl§] |= al |= al ==) 18] RIS = - lS < o SS =) gle = << =) o [=f ES < ofl zg 3 @ - wy — r— Ta) o Ua) [= wy
Ss [E28] B82] 19] 813] 3.18 les 5] IES = ll PEE SEES SIE a IS] SEIS clgic s|3le 5 | 8 < < eB < - < =a gn wold ofwn gl {o —1e 20 + BE I of. A s [2128] BIE | 131E SI5EE 2] EE EL BE IE] LE IS ? ; : 3 = qF =~ 3 on — = =
Vis © od Is < Sd Is] 3 PY 16] J al 15 JD © 3
S 8] = © Ze ® Re = a |& = ~ = R= ~ = = ve 5 (= S = op S — 2 = ~ ~ ~ = ~ ~ - ~ = Els Blas PI EE Bala) lel@lolsl [5l18]=le 3S Fi =1E=) =I] I NSS S|sjele o =) ola
I] cl 2 = 2 @ @ 2 E = E 0 2
SET EET EET | SER ERE
El |® Bl I® E| |® ® {I LS E ® = (= = [<= = [<= < = $ 3 of
NER ® |9 ?| |S 2 [8 =| | | 8 . l= ~ (a) ~ #13 ~ Le ~ IS 8 ~ 19) é Ia] |e => = wl |e 2 o
Z I~ wy ~ wn ni \n Le] ON \n Ue] BN NE~ Le] oll sl=l=l=iNlslglgl Nl Silla =) E = 22 Sl = 215g a2 3 s181317 1 8 sla 30 Es 2l Slo NN HE] 2
SRE HEH EE EEE HE EEE BE EEE HE EEN ME BER
Ena EEE tac Cae EERE ERE = 18 |e SIE BEE SI EYRE 1 ENE El EES
S Lo) ° ot} ° i) ° I) ™ : 9 od)
S| IF EIR IE IR a [F I ] IT sl I= SI a = |% INE SI 3 a0 « oe ae « ry 3 .. [-] - = af |S wl |& «| |S wl |& o| |S
CL ,
SA << 7a} 0 [al w i]. aN = < = if = oi <1 BN
Eo ; : = vinyl i] Mn =) I i 4 0 ow [=)} :
Sl IRIEL 18] IRIEL 18] 1§])E on on i — — =
I wl loo + 1) rn : hd hd — <=
I= 1 BE < IS < (9) <3 <3 = o = [=] <9 ay
Q on = a i — 79} | of ~ f ol wn 3 og 1 Oat NR I PO Eel
EE EE slelst | oieizls i gi < ‘a [3] < < < - | OQ of vice Of Wico
SEIS al ES al £18 cl=|o olZle =] B=) 8] 8) 8) 53 ISIE 15 . N — i.
At 121 1RI= 18 B=] (= =1 = Sle) |= SiS] |= - ~~ ~
Pl « ~ 1 hn | Bea 8 ba}
CLUE E RL
- <+ ® | | © ! | © g
TE bl Et Eley dy 2 ors oo} Sides
IE] Bee] I EE) EL] Ed ERS
MEI EIS 3 alel= ME EEE =f E13 I= ¥ EK] gl lin E > 2 = 2 ai CH : SLAF | IS 19 | 1S] IS 1553 I oe Bl I~ LIS I= 0 & Life = bY I= = |S 18] |= gl I=] [1+] |=
TN ETE BY CIES] pI EE 1 = ol =
BEE STE] BY REECE EE IE 2IRz Ela 21212 BIS EIR El B «
I INGHAEIE El PS i lat Po] i § [] ¥ ] i <3] I= ony o> IR wy J = I wy 5
ITI SS I Et TF I at Lod BO 4 I nd O-
HSI ¥ I= INES oy © = © - = << E = . = w «+ - =) [13 I~] ve - [4d [+ Q ~ ~ =] w [= AQ L]
EXAMPLE 22 :
Dosage formulations in accordance with this invention were prepared following the general procedure described in Example 20, using solubulizing agents composed of PEG 1450 from two different commercial sources (CS No. 1 and CS No. 2) to evaluate possible differences in formulation stability due to the influence of components of the solubulizing agent.
As shown in Table 8, dosage form solutions of
Compound Ia in a PEG 400/PEG 1450/Tween®80 composition including PEG 1450 from the two different commercial sources displayed marked differences in stability.
Claims (41)
1. A pharmaceutical composition comprising an orally- active taxane derivative having the formula: AN 0 NH 0 PN ” R Y Olle. T OH —F BzO £ 0 . 0) J o [o]
[0] 0 ls) ' aw IT NH v o™ £ I é Cen) IiH OH HO H H So (s) O Q ) S — o
] ® wherein: R is phenyl, isopropyl, or tert butyl; oo R' is -C(O)RZ in which RZ is (CH3)3CO-, (CH3)3CCHz-, CH3 (CHy) 30-, cyclobutyl-, cyclohexyloxy, or (2- furyl); and RZ is CH3C(0)0-, and a pharmaceutically acceptable solubulizing agent for said taxane derivative.
2. The composition as claimed in claim 1, wherein said compound is selected from the group consisting of compounds of formula I wherein R, R}, and R? are as follows: CE CC CA (CH3) 5000 07 - (C3) 500001 (CH 5CCR,C (01 - Bhenyl- [Cyelobuey1C(0)- (C3130 [CyelohexyIoc(o)- (C7 CCRC (0) - (C3) 3008 (07 - CHj (CHp) 30€ (0) - (C3) 36 [Cyelobuey1CTo)- (Fay TI C0)
3. The composition as claimed in claim 1, comprising a compound of formula I in which R represents tert butyl; R! represents (CH;3)3;COC(0)-; and R® represents CH3C (0) O-.
' .
4. The composition as claimed in claim 1, comprising ® from about 1 to about 20 wt% of said taxane derivative and from about 10 to about 99 wt% of said solubulizing agent.
5. The composition as claimed in claim 1, wherein said solubulizing agent consists essentially of at least one of the solubilizer compounds (a) a polyether glycol; (b) a saturated or unsaturated polyglycolized glyceride; or (e¢) a solid amphiphilic surfactant; and optionally, further includes (d) an alcohol other than a polyether glycol; (e) a fatty acid ester derivatives of a polyhydric alcohol; (f) a surfactant other than (¢); (g) vegetable oil; and (h) mineral oil or a mixture of any of (d) - (h).
6. The composition as claimed in claim 5, wherein said polyether glycol solubilizer compound is selected from the group consisting of a polyethylene glycol and a polyproplyene glycol and mixtures thereof.
7. The composition as claimed in claim 6, wherein said polyether glycol solubulizer compound comprises a polyethylene glycol.
8. The composition as claimed in claim 7, wherein the molecular weight of said polythylene glycol is in the range of 200 - 8000. :
® 9g. The composition as claimed in claim 5, wherein said polyglycolized glyceride solubilizer compound is saturated. To © 8
10. The composition as claimed in claim 5, wherein said solid amphiphilic surfactant solubulizer compound is selected from the group consisting of hydroxy- substituted stearic acid esters of polyethylene glycols and «<-tocopheryl-polyethylene succinate esters of polyethylene glycols.
11. The composition as claimed in claim 5, wherein said fatty acid ester derivative of said polyhydric alcohol is selected from the group consisting of medium chain fatty acid monoglycerides, medium chain fatty acid diglycerides, medium chain fatty acid triglycerides and mixtures of said mono- di- and triglycerides.’
12. The composition as claimed in claim 5, wherein said other surfactant is at least one surfactant selected from the group consisting of polyoxyethylene castor oil derivatives, polyoxethylene derivatives of fatty acid partial esters of sorbitan, polyoxyalkylene derivatives of propylene glycol, polyoxyethylene Stearates, sorbitan fatty acid esters and lecithin.
[} +
13. The composition as claimed in claim 5, wherein said ® vegetable oil is selected from the group consisting of soybean oil, olive oil, peanut oil and sunflower oil.
14. The composition as claimed in claim 5, wherein said pharmacetically acceptable solubulizing agent consists essentially of polyethylene glycol as said solubilizer compound.
15. The composition as claimed in claim 14, wherein said solubilizer compound includes polyethylene glycol which is liquid at room temperature and polyethylene glycol which is solid at room temperature.
16. The composition as claimed in claims 14 or 15 further comprising at least one surfactant other than said solid, amphiphilic surfactant.
17. The composition as claimed in claim 5, wherein said pharmaceutically acceptable bioavailability enhancing agent consists essentially of saturated polyglycolized glyceride as said solubulizer.
18. The composition as claimed in claim 5, wherein said . pharmaceutically acceptable solubulizing agent consists essentially of solid, amphiphilic oo surfactant as said solubulizer compound.
4. ’ + [} ® 19. The composition as claimed in claim 5, wherein said solubilizer compound is solid at room temperature.
20. The composition as claimed in claim 5, wherein said solubilizer compound is liquid at room temperature.
21. The composition as claimed in claim 5, comprising said taxane derivative and a solubulizing agent comprising a plurality of said solubilizer compounds .
22. The composition as claimed in claim 21, wherein at least one of said plurality of solubilizer compounds is solid at room temperature and at least one other of said plurality of solubilizers is liquid at room temperature.
23. A composition as claimed in claim 21, wherein said solubilizer compound comprises at least one polyether glycol and at least one polyglycolized glyceride.
24. The composition as claimed in claim 21, wherein said solubilizer compound comprises at least one polyether glycol and at least one solid amphiphilic surfactant. -75- FRAY
. PCT/US02/40127
25. The composition as claimed in claim 21, wherein said composition comprises 4 — 10 wt% of said taxane derivative, 15-60 wt% of said polyether glycol; 15 -60 wt% of said polyglycolized glyceride, 15-60 wt% of said amphiphilic surfactant and 5-40 wt% of a said other surfactant.
26. The composition as claimed in any one of claims 1, 2, 3, 14, 15, 16, 17, 18, 23 or 24 in unit dosage form comprising, per unit, from about 2 mg to about 25 mg of said taxane derivative.
27. The composition as claimed in claim 25, wherein said unit dosage form is enclosed in a capsule.
28. The composition as claimed in claim 1, further comprising a pharmaceutically acceptable acid.
29. The composition as claimed in claim 28, wherein said pharmaceutically acceptable acid comprises citric acid.
30. A method of inhibiting tumor growth in a mammalian host which comprises administering to said mammal a tumor-growth inhibiting amount of a composition as claimed in any of claims 1,2, 3,14, 15, 16, 17, 18, 23 or 24.
31. The method as claimed in claim 30, wherein the administration is oral.
32. Use of a composition as claimed in claim 1 in the manufacture of a preparation for treatment of cancer selected from the group consisting of ovarian, breast, brain, prostate, colon, 76 AMENDED SHEET
. PCT/US02/40127 ’ stomach, kidney, and/or testicular cancer, Karposi’'s sarcoma; cholangiocarcinoma; choriocarcinoma; neuroblastoma; Wilm's tumor, Hodgkin's disease; melanomas; multiple myelomas; chronic lymphocytic leukemias; and acute or chronic granulocytic lymphomas in a patient.
33. Use of a composition as claimed in any one of claims 1, 2, 3, 14, 15, 16, 17, 18, 23 or 24 in the manufacture of a preparation for inhibiting tumor growth in a mammalian host.
34. A substance or composition for use in a method of inhibiting tumor growth in a mammalian host, said substance or composition comprising a composition as claimed in any of claims 1, 2,3, 14, 15, 16, 17, 18, 23 or 24, and said method comprising administering to said mammal a tumor-growth inhibiting amount of said substance or composition.
35. A substance or composition for use in a method of treatment as claimed in claim 34, wherein the administration is oral.
36. A substance or composition for use in a method for treatment of a cancer selected from the group consisting of ovarian, breast, brain, prostate, colon, stomach, kidney, and/or testicular cancer, Karposi’s sarcoma; cholangiocarcinoma; choriocarcinoma; neuroblastoma; Wilm’s tumor, Hodgkin's disease; melanomas; multiple myelomas; chronic lymphocytic leukemias; and acute or chronic granulocytic lymphomas ina patient in need of said treatment, said substance or composition comprising a pharmaceutical composition as claimed in claim 1, and said method comprising administering said substance or composition to said patient . : 77 AMENDED SHEET
- PCT/US02/40127
37. A composition as claimed in any one of claims 1 to 29, substantially as herein described and illustrated.
38. A method as claimed in claim 30 or claim 31, substantially as herein described and illustrated.
39. Use as claimed in claim 32 or claim 33, substantially as herein described and illustrated.
40. A substance or composition for use in a method of treatment as claimed in any one of claims 34 to 36, substantially as herein described and illustrated. 156
41. A new composition, a new non-therapeutic method of treatment, a new use of a composition as claimed in any one of claims 1, 2, 3, 14, 15, 16, 17, 18, 23 or 24, or a substance or composition for a new use in a method of treatment, substantially as herein described. oo 78 AMENDED SHEET
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US34288901P | 2001-12-20 | 2001-12-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200404584B true ZA200404584B (en) | 2005-09-13 |
Family
ID=23343716
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200404584A ZA200404584B (en) | 2001-12-20 | 2004-06-09 | Pharmaceutical compositions of orally active taxane derivatives having enhanced bioavailability. |
Country Status (24)
Country | Link |
---|---|
US (1) | US20030220391A1 (en) |
EP (1) | EP1465618A2 (en) |
JP (1) | JP2006501134A (en) |
KR (1) | KR20040066921A (en) |
CN (1) | CN1273130C (en) |
AR (1) | AR037951A1 (en) |
AU (1) | AU2002361701A1 (en) |
BR (1) | BR0215184A (en) |
CA (1) | CA2470826A1 (en) |
GE (1) | GEP20063806B (en) |
HR (1) | HRP20040545A2 (en) |
HU (1) | HUP0500843A2 (en) |
IL (1) | IL162118A0 (en) |
IS (1) | IS7306A (en) |
MX (1) | MXPA04005877A (en) |
NO (1) | NO20043101L (en) |
PE (1) | PE20030742A1 (en) |
PL (1) | PL374283A1 (en) |
RS (1) | RS52904A (en) |
RU (1) | RU2004119557A (en) |
TW (1) | TW200302086A (en) |
UY (1) | UY27598A1 (en) |
WO (1) | WO2003053350A2 (en) |
ZA (1) | ZA200404584B (en) |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1642576A (en) * | 2002-02-25 | 2005-07-20 | 药物发展有限公司 | Absorption enhancing agent |
US6855332B2 (en) * | 2002-07-03 | 2005-02-15 | Lyfjathroun Hf. | Absorption promoting agent |
KR100533458B1 (en) | 2002-07-20 | 2005-12-07 | 대화제약 주식회사 | Composition for solubilization of paclitaxel and preparation method thereof |
EP1498120A1 (en) * | 2003-07-18 | 2005-01-19 | Aventis Pharma S.A. | Semi-solid formulations for the oral administration of taxoids |
CN1886400A (en) | 2003-09-25 | 2006-12-27 | 泰普斯特医药公司 | 9, 10-alpha, alpha-OH-taxane analogs and methods for production thereof |
US20060088591A1 (en) * | 2004-10-22 | 2006-04-27 | Jinghua Yuan | Tablets from a poorly compressible substance |
US20060116420A1 (en) * | 2004-11-23 | 2006-06-01 | Ramakrishnan Chidambaram | Crystalline forms of 3'-tert-Butyl-3'-N-tert-butyloxycarbonyl-4-deacetyl-3'-dephenyl-3'-N-debenzoyl-4-O-methoxycarbonyl-paclitaxel |
AU2012202903B2 (en) * | 2005-02-18 | 2014-12-11 | Abraxis Bioscience, Inc. | Drugs with improved hydrophobicity for incorporation in medical devices |
EP3345632A1 (en) * | 2005-02-18 | 2018-07-11 | Abraxis BioScience, LLC | Drugs with improved hydrophobicity for incorporation in medical devices |
BRPI0613005A8 (en) * | 2005-07-15 | 2017-12-26 | Angiochem Inc | use of aprotinin polypeptides as carriers in pharmaceutical conjugates. |
US20070015834A1 (en) * | 2005-07-18 | 2007-01-18 | Moshe Flashner-Barak | Formulations of fenofibrate containing PEG/Poloxamer |
CA2620585C (en) | 2005-08-31 | 2015-04-28 | Abraxis Bioscience, Llc | Compositions comprising poorly water soluble pharmaceutical agents and antimicrobial agents |
WO2007134354A1 (en) * | 2006-05-23 | 2007-11-29 | Ebewe Pharma Ges.M.B.H. Nfg. Kg | Pharmaceutical formulation |
US11786504B2 (en) | 2006-09-28 | 2023-10-17 | Tapestry Pharmaceuticals, Inc. | Taxane analogs for the treatment of brain cancer |
WO2008121476A1 (en) | 2007-03-28 | 2008-10-09 | Tapestry Pharmaceuticals, Inc. | Biologically active taxane analogs and methods of treatment by oral administration |
US11873308B2 (en) | 2006-11-06 | 2024-01-16 | Tapestry Pharmaceuticals, Inc. | Biologically active taxane analogs and methods of treatment by oral administration |
EP1946747A1 (en) * | 2007-01-17 | 2008-07-23 | Sandoz AG | Pharmaceutical composition of improved stability containing taxane derivatives |
WO2008109360A1 (en) | 2007-02-28 | 2008-09-12 | Tapestry Pharmaceuticals, Inc | Taxane analogs for the treatment of brain cancer |
US9089544B2 (en) * | 2007-08-24 | 2015-07-28 | Slotervaart Participaties Bv | Composition |
EP2190413B1 (en) * | 2007-08-24 | 2015-01-28 | Stichting Het Nederlands Kanker Instituut | Compositions for the treatment of neoplastic diseases |
EP2316422A1 (en) * | 2007-11-12 | 2011-05-04 | Novartis AG | Liquid compositions comprising valsartan |
EP2077132A1 (en) | 2008-01-02 | 2009-07-08 | Boehringer Ingelheim Pharma GmbH & Co. KG | Dispensing device, storage device and method for dispensing a formulation |
ES2344674B1 (en) | 2008-08-07 | 2011-06-29 | Gp Pharm, S.A. | INJECTABLE PHARMACEUTICAL COMPOSITION OF TAXANOS. |
BRPI0920209A2 (en) | 2008-10-15 | 2015-12-22 | Angiochem Inc | conjugates of glp-1 agonists and their uses |
JP5670421B2 (en) | 2009-03-31 | 2015-02-18 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Component surface coating method |
EP2432531B1 (en) | 2009-05-18 | 2019-03-06 | Boehringer Ingelheim International GmbH | Adapter, inhalation device and nebulizer |
CN102038635A (en) | 2009-10-23 | 2011-05-04 | 天津天士力集团有限公司 | Taxane medicine solution containing pH value regulator and preparation method thereof |
US10016568B2 (en) | 2009-11-25 | 2018-07-10 | Boehringer Ingelheim International Gmbh | Nebulizer |
CA2781792C (en) | 2009-11-25 | 2019-04-02 | Boehringer Ingelheim International Gmbh | Nebulizer |
WO2011064163A1 (en) | 2009-11-25 | 2011-06-03 | Boehringer Ingelheim International Gmbh | Nebulizer |
WO2011160932A1 (en) | 2010-06-24 | 2011-12-29 | Boehringer Ingelheim International Gmbh | Nebulizer |
EP2694220B1 (en) | 2011-04-01 | 2020-05-06 | Boehringer Ingelheim International GmbH | Medical device comprising a container |
US9827384B2 (en) | 2011-05-23 | 2017-11-28 | Boehringer Ingelheim International Gmbh | Nebulizer |
WO2013152894A1 (en) | 2012-04-13 | 2013-10-17 | Boehringer Ingelheim International Gmbh | Atomiser with coding means |
EP2777691A1 (en) * | 2013-03-14 | 2014-09-17 | Pharmachemie B.V. | Taxoid - Purification of Liquid Excipients |
EP3030298B1 (en) | 2013-08-09 | 2017-10-11 | Boehringer Ingelheim International GmbH | Nebulizer |
PL2835146T3 (en) | 2013-08-09 | 2021-04-06 | Boehringer Ingelheim International Gmbh | Nebulizer |
US10195374B2 (en) | 2014-05-07 | 2019-02-05 | Boehringer Ingelheim International Gmbh | Container, nebulizer and use |
US10722666B2 (en) | 2014-05-07 | 2020-07-28 | Boehringer Ingelheim International Gmbh | Nebulizer with axially movable and lockable container and indicator |
ES2913297T3 (en) | 2014-05-07 | 2022-06-01 | Boehringer Ingelheim Int | nebulizer |
CN103980232A (en) * | 2014-06-05 | 2014-08-13 | 北京诺普德医药科技有限公司 | 10-acetyldocetaxel and application thereof |
JP6823055B2 (en) | 2015-06-15 | 2021-01-27 | アンジオケム インコーポレーテッド | How to treat soft meningeal carcinomatosis |
TWI715636B (en) * | 2015-09-30 | 2021-01-11 | 香港商慧源香港創新有限公司 | Oral taxane compositions and methods |
CN108066335B (en) * | 2016-11-11 | 2020-02-21 | 北京康辰药业股份有限公司 | A pharmaceutical composition containing paclitaxel or its analogues and its preparation method |
FR3113238B1 (en) | 2020-08-05 | 2024-04-05 | Gattefosse Sas | USE AS AN EXCIPIENT OF A MIXTURE OF LAURIC MACROGOLGLYCERIDE AND POLYETHYLENE GLYCOL |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2601675B1 (en) * | 1986-07-17 | 1988-09-23 | Rhone Poulenc Sante | TAXOL DERIVATIVES, THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
US4960790A (en) * | 1989-03-09 | 1990-10-02 | University Of Kansas | Derivatives of taxol, pharmaceutical compositions thereof and methods for the preparation thereof |
US5817321A (en) * | 1992-10-08 | 1998-10-06 | Supratek Pharma, Inc. | Biological agent compositions |
CA2308082A1 (en) * | 1992-11-27 | 1994-06-09 | Paul Handreck | Injectable compostion |
US6964946B1 (en) * | 1995-10-26 | 2005-11-15 | Baker Norton Pharmaceuticals, Inc. | Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same |
US6395770B1 (en) * | 1995-10-26 | 2002-05-28 | Baker Norton Pharmaceuticals, Inc. | Method and compositions for administering taxanes orally to human patients |
US6245805B1 (en) * | 1995-10-26 | 2001-06-12 | Baker Norton Pharmaceuticals, Inc. | Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents |
HU226646B1 (en) * | 1996-03-12 | 2009-05-28 | Pg Txl Company | Water soluble pharmaceutical compositions containing taxane derivatives |
US5756537A (en) * | 1996-11-08 | 1998-05-26 | Parkash S. Gill, M.D., Inc. | Regime for paclitaxel in Kaposi's sarcoma patients |
US6515016B2 (en) * | 1996-12-02 | 2003-02-04 | Angiotech Pharmaceuticals, Inc. | Composition and methods of paclitaxel for treating psoriasis |
US6495579B1 (en) * | 1996-12-02 | 2002-12-17 | Angiotech Pharmaceuticals, Inc. | Method for treating multiple sclerosis |
US5980936A (en) * | 1997-08-07 | 1999-11-09 | Alliance Pharmaceutical Corp. | Multiple emulsions comprising a hydrophobic continuous phase |
EP1067923A4 (en) * | 1997-12-31 | 2002-11-13 | Bristol Myers Squibb Co | 2-aroyl-4-acyl paclitaxel (taxol) analogs |
IL131217A0 (en) * | 1998-03-10 | 2001-01-28 | Napro Biotherapeutics Inc | Novel methods and compositions for delivery of taxanes |
US6979456B1 (en) * | 1998-04-01 | 2005-12-27 | Jagotec Ag | Anticancer compositions |
MXPA01011046A (en) * | 1999-05-17 | 2002-07-22 | Squibb Bristol Myers Co | Novel reaction conditions for the cleavage of silyl ethers in the preparation of paclitaxel (taxol(r)) and paclitaxel analogues. |
MXPA02001396A (en) * | 1999-08-11 | 2002-08-12 | Bristol & Minus | Process for the preparation of a paclitaxel c-4 methyl carbonate analog. |
US6136846A (en) * | 1999-10-25 | 2000-10-24 | Supergen, Inc. | Formulation for paclitaxel |
US6750246B1 (en) * | 2000-02-03 | 2004-06-15 | Bristol-Myers Squibb Company | C-4 carbonate taxanes |
US6916942B2 (en) * | 2000-02-03 | 2005-07-12 | Bristol-Myers Squibb Company | Process for the preparation of C-4 carbonate taxanes |
TWI310684B (en) * | 2000-03-27 | 2009-06-11 | Bristol Myers Squibb Co | Synergistic pharmaceutical kits for treating cancer |
WO2002043765A2 (en) * | 2000-11-28 | 2002-06-06 | Transform Pharmaceuticals, Inc. | Pharmaceutical formulations comprising paclitaxel, derivatives, and pharmaceutically acceptable salts thereof |
TWI297335B (en) * | 2001-07-10 | 2008-06-01 | Synta Pharmaceuticals Corp | Taxol enhancer compounds |
WO2003045357A1 (en) * | 2001-11-27 | 2003-06-05 | Transform Pharmaceuticals, Inc. | Oral pharmaceutical formulations comprising paclitaxel, derivatives and methods of administration thereof |
-
2002
- 2002-12-12 AU AU2002361701A patent/AU2002361701A1/en not_active Abandoned
- 2002-12-12 EP EP02797339A patent/EP1465618A2/en not_active Withdrawn
- 2002-12-12 BR BRPI0215184-7A patent/BR0215184A/en not_active IP Right Cessation
- 2002-12-12 PL PL02374283A patent/PL374283A1/en not_active Application Discontinuation
- 2002-12-12 CA CA002470826A patent/CA2470826A1/en not_active Abandoned
- 2002-12-12 WO PCT/US2002/040127 patent/WO2003053350A2/en active Application Filing
- 2002-12-12 HU HU0500843A patent/HUP0500843A2/en unknown
- 2002-12-12 RU RU2004119557/15A patent/RU2004119557A/en not_active Application Discontinuation
- 2002-12-12 RS YU52904A patent/RS52904A/en unknown
- 2002-12-12 KR KR10-2004-7009593A patent/KR20040066921A/en not_active Application Discontinuation
- 2002-12-12 IL IL16211802A patent/IL162118A0/en unknown
- 2002-12-12 CN CNB028254708A patent/CN1273130C/en not_active Expired - Fee Related
- 2002-12-12 GE GE5614A patent/GEP20063806B/en unknown
- 2002-12-12 JP JP2003554110A patent/JP2006501134A/en not_active Withdrawn
- 2002-12-16 TW TW091136275A patent/TW200302086A/en unknown
- 2002-12-19 AR ARP020105039A patent/AR037951A1/en unknown
- 2002-12-19 US US10/323,551 patent/US20030220391A1/en not_active Abandoned
- 2002-12-20 UY UY27598A patent/UY27598A1/en not_active Application Discontinuation
-
2003
- 2003-01-06 PE PE2003000013A patent/PE20030742A1/en not_active Application Discontinuation
-
2004
- 2004-06-09 ZA ZA200404584A patent/ZA200404584B/en unknown
- 2004-06-10 IS IS7306A patent/IS7306A/en unknown
- 2004-06-15 HR HR20040545A patent/HRP20040545A2/en not_active Application Discontinuation
- 2004-06-16 MX MXPA04005877A patent/MXPA04005877A/en unknown
- 2004-07-19 NO NO20043101A patent/NO20043101L/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
PL374283A1 (en) | 2005-10-03 |
WO2003053350A3 (en) | 2004-01-15 |
MXPA04005877A (en) | 2004-09-13 |
RU2004119557A (en) | 2005-04-20 |
BR0215184A (en) | 2006-06-06 |
JP2006501134A (en) | 2006-01-12 |
UY27598A1 (en) | 2003-07-31 |
AU2002361701A1 (en) | 2003-07-09 |
KR20040066921A (en) | 2004-07-27 |
HUP0500843A2 (en) | 2005-12-28 |
WO2003053350A2 (en) | 2003-07-03 |
CA2470826A1 (en) | 2003-07-03 |
PE20030742A1 (en) | 2003-09-02 |
AR037951A1 (en) | 2004-12-22 |
RS52904A (en) | 2006-12-15 |
HRP20040545A2 (en) | 2005-08-31 |
IS7306A (en) | 2004-06-10 |
EP1465618A2 (en) | 2004-10-13 |
CN1606437A (en) | 2005-04-13 |
CN1273130C (en) | 2006-09-06 |
IL162118A0 (en) | 2005-11-20 |
TW200302086A (en) | 2003-08-01 |
NO20043101L (en) | 2004-07-19 |
GEP20063806B (en) | 2006-04-25 |
US20030220391A1 (en) | 2003-11-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA200404584B (en) | Pharmaceutical compositions of orally active taxane derivatives having enhanced bioavailability. | |
AU2001277099B2 (en) | Self-emulsifying drug delivery systems for extremely water-insoluble, lipophilic drugs | |
CN1313154C (en) | Medicine composition of adding active component which undissolved in water in carrier composition and its preparing method | |
US10543196B2 (en) | Oral dosage forms of bendamustine | |
US20070104780A1 (en) | Formulation comprising a drug of low water solubility and method of use thereof | |
ES2326783T3 (en) | COMPOSITIONS OF N-BENZOILESTAUROSPORINA SPONTANEAMY DISPERSABLE. | |
DK2575784T3 (en) | ORAL DOSAGE FORMS OF BENDAMUSTIN | |
US20210113477A1 (en) | Pharmaceutical formulations | |
KR101739820B1 (en) | Pharmaceutical composition in form of non-aqueous liquid comprising revaprazan or its salt | |
AU2011276552B2 (en) | Oral formulation of kinase inhibitors | |
EP3362046A1 (en) | Fulvestrant compositions | |
KR20010078703A (en) | New Pharmaceutical Formulation | |
KR101612259B1 (en) | Pharmaceutical composition for oral administration comprising taxanes in high concentration | |
US20050220866A1 (en) | Novel capsule formulations of etoposide for oral use | |
AU2022339721A1 (en) | Formulations with enhanced sn-38 solubility and oral absorption | |
CN114344309A (en) | Allopregnanolone derivative self-emulsifying preparation and preparation method thereof | |
EA010293B1 (en) | Particle-forming compositions containing fused pyrrolocarbazoles |